JP2018509135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509135A5 JP2018509135A5 JP2017518096A JP2017518096A JP2018509135A5 JP 2018509135 A5 JP2018509135 A5 JP 2018509135A5 JP 2017518096 A JP2017518096 A JP 2017518096A JP 2017518096 A JP2017518096 A JP 2017518096A JP 2018509135 A5 JP2018509135 A5 JP 2018509135A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- cell
- mhc
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020102005A JP7358299B2 (ja) | 2014-12-23 | 2020-06-12 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102992A JP7346361B2 (ja) | 2014-12-23 | 2020-06-15 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102993A JP7448423B2 (ja) | 2014-12-23 | 2020-06-15 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2021052978A JP7713309B2 (ja) | 2014-12-23 | 2021-03-26 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096165P | 2014-12-23 | 2014-12-23 | |
| GB1423016.3 | 2014-12-23 | ||
| GB201423016 | 2014-12-23 | ||
| US62/096,165 | 2014-12-23 | ||
| GB1501017.6 | 2015-01-21 | ||
| GBGB1501017.6A GB201501017D0 (en) | 2014-12-23 | 2015-01-21 | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| PCT/EP2015/080018 WO2016102272A1 (en) | 2014-12-23 | 2015-12-16 | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers |
Related Child Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020102004A Division JP7109801B2 (ja) | 2014-12-23 | 2020-06-12 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102006A Division JP2020191866A (ja) | 2014-12-23 | 2020-06-12 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102005A Division JP7358299B2 (ja) | 2014-12-23 | 2020-06-12 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102992A Division JP7346361B2 (ja) | 2014-12-23 | 2020-06-15 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102991A Division JP2020191867A (ja) | 2014-12-23 | 2020-06-15 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020102993A Division JP7448423B2 (ja) | 2014-12-23 | 2020-06-15 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2020106475A Division JP7026411B2 (ja) | 2014-12-23 | 2020-06-19 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2021052978A Division JP7713309B2 (ja) | 2014-12-23 | 2021-03-26 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509135A JP2018509135A (ja) | 2018-04-05 |
| JP2018509135A5 true JP2018509135A5 (enExample) | 2018-09-27 |
| JP6906156B2 JP6906156B2 (ja) | 2021-07-21 |
Family
ID=52630910
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518096A Expired - Fee Related JP6906156B2 (ja) | 2014-12-23 | 2015-12-16 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2021052978A Active JP7713309B2 (ja) | 2014-12-23 | 2021-03-26 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021052978A Active JP7713309B2 (ja) | 2014-12-23 | 2021-03-26 | 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ |
Country Status (25)
| Country | Link |
|---|---|
| US (8) | US10064926B2 (enExample) |
| EP (8) | EP3620168A1 (enExample) |
| JP (2) | JP6906156B2 (enExample) |
| KR (1) | KR102284493B1 (enExample) |
| CN (4) | CN112646021A (enExample) |
| AR (2) | AR103220A1 (enExample) |
| AU (3) | AU2015371490B2 (enExample) |
| BR (1) | BR112017008972A2 (enExample) |
| CA (1) | CA2972126A1 (enExample) |
| CL (1) | CL2017001391A1 (enExample) |
| CR (1) | CR20170282A (enExample) |
| DK (4) | DK3626731T3 (enExample) |
| EA (2) | EA202190587A3 (enExample) |
| GB (1) | GB201501017D0 (enExample) |
| IL (1) | IL250989B (enExample) |
| MA (3) | MA41237B1 (enExample) |
| MX (1) | MX377144B (enExample) |
| PE (1) | PE20170940A1 (enExample) |
| PH (1) | PH12017500484B1 (enExample) |
| PL (1) | PL3236985T5 (enExample) |
| RS (4) | RS62448B1 (enExample) |
| SG (1) | SG11201703322UA (enExample) |
| SI (3) | SI3626729T1 (enExample) |
| TW (1) | TWI687436B (enExample) |
| WO (1) | WO2016102272A1 (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| WO2015164826A2 (en) * | 2014-04-24 | 2015-10-29 | Rhode Island Hospital | ASPARTATE-β-HYDROXYLASE INDUCES EPITOPE-SPECIFIC T CELL RESPONSES IN TUMORS |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| MX375970B (es) | 2014-12-23 | 2025-03-06 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos. |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| MA50819A (fr) | 2014-12-23 | 2021-04-07 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| PH12022551111A1 (en) | 2015-10-05 | 2023-08-23 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| US11020429B2 (en) | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| JP7114477B2 (ja) | 2015-12-16 | 2022-08-08 | グリットストーン バイオ インコーポレイテッド | 新生抗原の特定、製造、および使用 |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| JP7042812B2 (ja) | 2016-06-20 | 2022-03-28 | ノバルティス アーゲー | トリアゾロピリミジン化合物の結晶形態 |
| US10689378B2 (en) | 2016-06-20 | 2020-06-23 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| JP2019524872A (ja) | 2016-06-20 | 2019-09-05 | ノバルティス アーゲー | 癌の治療に有用なイミダゾピリミジン化合物 |
| PL3522905T3 (pl) * | 2016-10-07 | 2025-01-07 | Io Biotech Aps | Immunogenne peptydy arginazowe |
| EP3529347A1 (en) | 2016-10-19 | 2019-08-28 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| AU2018212584B2 (en) * | 2017-01-27 | 2020-12-10 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| EP3638695A4 (en) * | 2017-06-14 | 2021-06-30 | Icahn School of Medicine at Mount Sinai | METHOD OF DETECTION AND TREATMENT OF IMMUNOTHERAPY-RESPONDING CLASSES OF HEPATOCELLULAR CARCINOMA |
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| WO2019030311A1 (en) * | 2017-08-09 | 2019-02-14 | Pamgene Bv | METHOD OF PREDICTING THE RESPONSE OF PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA TO A MEDICINAL PRODUCT |
| GB201713700D0 (en) * | 2017-08-25 | 2017-10-11 | Anastasis Biotec Ltd | Peptide conjugates |
| CN111465989B (zh) | 2017-10-10 | 2024-06-25 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
| AU2018373154B2 (en) | 2017-11-22 | 2025-08-07 | Seattle Project Corp. | Reducing junction epitope presentation for neoantigens |
| CN114900773A (zh) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
| CA3101310A1 (en) * | 2018-03-12 | 2019-09-19 | The Children's Hospital Of Philadelphia | Methods and compositions for use of tumor self-antigens in adoptive immunotherapy |
| EP3802568A4 (en) | 2018-06-08 | 2022-07-13 | The Board of Regents of the University of Oklahoma | PEPTIDE THERAPEUTICS USED TO TREAT ALZHEIMER'S DISEASE AND RELATED DISEASES |
| DE102018122546B3 (de) * | 2018-09-14 | 2019-12-05 | Immatics Biotechnologies Gmbh | Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden |
| GB201815549D0 (en) | 2018-09-24 | 2018-11-07 | Io Biotech Aps | Arginase1 polypeptides |
| EP3870694A4 (en) * | 2018-10-26 | 2022-08-17 | Tami Bar | COMPOSITIONS AND METHODS FOR BIODEGRADING ALCOHOL |
| CN109663128A (zh) * | 2018-11-21 | 2019-04-23 | 中国农业大学 | 一种肺动脉高压标志物及其作为治疗靶点的应用 |
| JP2022512384A (ja) * | 2018-12-13 | 2022-02-03 | ロード アイランド ホスピタル | Ａｓｐｈ発現腫瘍の成長および進行の阻害 |
| EP3721899A1 (en) | 2019-04-08 | 2020-10-14 | China Medical University | Combination therapies comprising dendritic cells-based vaccine and immune checkpoint inhibitor |
| CN110850086B (zh) * | 2019-11-18 | 2023-05-02 | 西安交通大学 | 一种肝移植术后缺血性胆道病变血清诊断标志物acly的应用 |
| CN113461798A (zh) * | 2020-03-18 | 2021-10-01 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用 |
| EP4130747A4 (en) * | 2020-03-30 | 2024-10-30 | Rophelbio Co., Ltd.a | Biomarker for cancer immunotherapy and use thereof |
| WO2021236638A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
| CN116333995A (zh) * | 2020-07-14 | 2023-06-27 | 广州泛恩生物科技有限公司 | 基于cxcr6阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用 |
| CN112063718A (zh) * | 2020-09-18 | 2020-12-11 | 中国医科大学 | Usp14在肝细胞肝癌诊断、预后判断以及治疗中的应用 |
| CN112043722B (zh) * | 2020-09-25 | 2022-02-15 | 中国医科大学 | Prpf6在前列腺癌及去势抵抗前列腺癌治疗中的应用 |
| CN114574486B (zh) * | 2020-12-01 | 2024-04-16 | 中国科学院大连化学物理研究所 | 作用于OPLAH的siRNA、DNA及构建物和应用 |
| JP2024508677A (ja) * | 2021-02-05 | 2024-02-28 | アマゾン テクノロジーズ インコーポレイテッド | 個別化がんワクチン用ネオアンチゲンのランク付け |
| CN114163510B (zh) * | 2021-03-24 | 2024-12-06 | 深圳市新靶向生物科技有限公司 | 一种与肝癌驱动基因突变相关的抗原肽组合及其应用 |
| US20250282887A1 (en) | 2021-04-02 | 2025-09-11 | Amgen Inc. | Mageb2 binding constructs |
| CA3226568A1 (en) * | 2021-07-19 | 2023-01-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Mct11 antibodies to treat t cell functional exhaustion and enhance cancer immunotherapy |
| CN115634281B (zh) * | 2021-07-20 | 2025-12-02 | 肖伯端 | Ctrp3蛋白的抗瘤作用及编码其的重组溶瘤病毒及制备方法和应用 |
| CN113502300B (zh) * | 2021-07-21 | 2024-02-06 | 徐州医科大学 | 一种含有hdac10基因启动子序列和报告基因的重组质粒、制备方法及应用 |
| CN118265721A (zh) * | 2021-10-18 | 2024-06-28 | 得克萨斯州大学系统董事会 | 靶向ndc80抗原的肽和经改造t细胞受体及使用方法 |
| CN115572764B (zh) * | 2022-03-30 | 2024-06-21 | 江苏鹍远生物技术有限公司 | 一组肿瘤检测标志物及其用途 |
| CN116334031A (zh) * | 2022-07-21 | 2023-06-27 | 中国人民解放军陆军军医大学 | 三个多肽及其在制备ⅰ型糖尿病免疫防治疫苗或药物中的应用 |
| CN116042825B (zh) * | 2022-09-28 | 2025-07-01 | 南方医科大学 | 一种评估5-fu治疗胃癌癌敏感性的探针引物组及其试剂盒 |
| WO2024235848A1 (en) * | 2023-05-12 | 2024-11-21 | Fundación Para La Investigación Médica Aplicada | Novel t cell receptors |
| EP4750807A1 (en) | 2023-07-27 | 2026-06-03 | Immatics Biotechnologies GmbH | Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same |
| EP4750806A1 (en) | 2023-07-27 | 2026-06-03 | Immatics Biotechnologies GmbH | Antigen binding proteins against mageb2 |
| WO2026033136A1 (en) | 2024-08-09 | 2026-02-12 | Immatics Biotechnologies Gmbh | Advanced treatment modalities for anti-prame tcr-engineered immune cells |
| CN119524137B (zh) * | 2024-12-11 | 2026-06-05 | 徐州医科大学 | Fbxo22在诊断、治疗非酒精性脂肪性肝病中的应用 |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| YU44186B (en) | 1978-12-22 | 1990-04-30 | Biogen Nv | Process for obtaining recombinant dnk molecules |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US6805861B2 (en) | 1996-01-17 | 2004-10-19 | Imperial College Innovations Limited | Immunotherapy using cytotoxic T lymphocytes (CTL) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20020061552A1 (en) * | 1999-12-17 | 2002-05-23 | Dong Yan | Mammalian dishevelled-associated proteins |
| WO2001062908A2 (en) | 2000-02-22 | 2001-08-30 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
| EP1294748B1 (en) | 2000-03-27 | 2010-06-30 | Technion Research and Development of Foundation, Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| EP2322228B1 (en) | 2000-06-05 | 2018-01-10 | Altor BioScience Corporation | T cell receptor fusion proteins and conjugates and methods of use thereof |
| US20020048550A1 (en) | 2000-07-20 | 2002-04-25 | Vallera Daniel A. | Radiolabeled immunotoxins |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US20050053918A1 (en) | 2001-05-16 | 2005-03-10 | Technion Research & Development Foundation Ltd. | Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| US7311914B2 (en) | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
| TW200413406A (en) * | 2002-08-26 | 2004-08-01 | Kirin Brewery | Peptides and drugs containing the same |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| EP2048159B1 (en) | 2002-11-09 | 2014-01-01 | Immunocore Ltd. | T cell receptor display |
| US20040096982A1 (en) | 2002-11-19 | 2004-05-20 | International Business Machines Corporation | Methods and apparatus for analysis of mass spectra |
| DE602004015064D1 (de) * | 2003-01-06 | 2008-08-28 | Wyeth Corp | Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US20090075304A1 (en) | 2004-05-27 | 2009-03-19 | Weidanz Jon A | Methods of assaying vaccine potency |
| US20090233318A1 (en) | 2004-12-28 | 2009-09-17 | Weidanz Jon A | Methods of assaying vaccine potency |
| US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| SI1760089T1 (sl) | 2005-09-05 | 2009-12-31 | Immatics Biotechnologies Gmbh | S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku |
| DE602005020046D1 (de) | 2005-09-05 | 2010-04-29 | Immatics Biotechnologies Gmbh | Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden |
| CA2660286A1 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| NZ582823A (en) * | 2007-07-27 | 2012-04-27 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| RS54204B1 (sr) * | 2007-07-27 | 2015-12-31 | Immatics Biotechnologies Gmbh | Nova imunoterapija protiv tumora mozga |
| WO2009026547A1 (en) | 2007-08-22 | 2009-02-26 | Receptor Logi, Ltd. | Methods of assaying vaccine potency |
| PT2201100E (pt) * | 2007-09-14 | 2016-06-03 | Univ Brussel Vrije | Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação |
| WO2009108372A2 (en) * | 2008-02-27 | 2009-09-03 | Receptor Logic, Inc. | Antibodies as t cell receptor mimics, methods of production and uses thereof |
| ME02267B (me) * | 2008-03-27 | 2016-04-28 | Immatics Biotechnologies Gmbh | Nova imunoterapija protiv tumora nervnih ćelija i mozga |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| WO2009151487A1 (en) * | 2008-06-13 | 2009-12-17 | Receptor Logic, Inc. | Methods of assaying vaccine potency |
| DE102008049136B4 (de) | 2008-09-26 | 2012-10-25 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. | Neue Regulatoren des angeborenen Immunsystems |
| ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| AU2010319323B2 (en) | 2009-11-14 | 2015-01-15 | Cardiovax, Llc | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis |
| US8506964B2 (en) | 2010-02-05 | 2013-08-13 | Cardiovax, Llc | Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| EP2632955A1 (en) | 2010-10-26 | 2013-09-04 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| AU2011325948A1 (en) | 2010-11-12 | 2013-05-30 | Cedars-Sinai Medical Center | Immunomodulatory compositions, methods and systems comprising immunogenic fragments of Apob100 |
| JP2013544243A (ja) | 2010-11-12 | 2013-12-12 | シーダース シナイ メディカル センター | 動脈瘤の治療及び／又は予防のための免疫調節方法及びシステム |
| WO2012074725A2 (en) | 2010-11-12 | 2012-06-07 | Cedars-Sinai Medical Center | Immunomodulatory methods and systems for treatment and/or prevention of hypertension |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| WO2013070603A1 (en) * | 2011-11-11 | 2013-05-16 | Cedars-Sinai Medical Center | Compositions and methods for treatment of kidney diseases |
| GB201208293D0 (en) * | 2012-05-11 | 2012-06-20 | Circassia Ltd | Hydrochlorice salt of peptide |
| HK1212236A1 (en) * | 2012-09-05 | 2016-06-10 | University Of Virginia Patent Foundation | Target peptides for colorectal cancer therapy and diagnostics |
| WO2014071978A1 (en) | 2012-11-08 | 2014-05-15 | Roche Diagnostics Gmbh | Nucleic acids encoding chimeric polypeptides for library screening |
| GB201301632D0 (en) * | 2013-01-30 | 2013-03-13 | Imp Innovations | Complement System |
| WO2014160275A2 (en) * | 2013-03-14 | 2014-10-02 | Battell Memorial Institute | Biomarkers for liver fibrosis |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| CN103739667B (zh) * | 2013-09-24 | 2017-08-25 | 上海宇研生物技术有限公司 | 卵巢癌特异的肿瘤抗原肽及其制备方法 |
| ES2740930T3 (es) | 2014-03-14 | 2020-02-07 | Immunocore Ltd | Bibliotecas de TCR |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| US20180179283A1 (en) | 2015-06-08 | 2018-06-28 | Adicet Bio Inc. | T cell receptor like antibodies having fine specificity |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| KR20190065189A (ko) | 2016-04-08 | 2019-06-11 | 어댑티뮨 리미티드 | T 세포 수용체 |
| MX395611B (es) | 2016-04-08 | 2025-03-25 | Adaptimmune Ltd | Receptores de celulas t. |
| MX2018012265A (es) | 2016-04-08 | 2019-02-07 | Adaptimmune Ltd | Receptores de celulas t. |
| CN109845298B (zh) | 2016-07-27 | 2021-12-28 | 夏普株式会社 | 使用系统信息值标签的无线电信方法和装置 |
| US20200325244A1 (en) | 2020-05-18 | 2020-10-15 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| EP3573997A4 (en) | 2017-01-24 | 2020-12-09 | Abexxa Biologics, Inc. | METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER |
| ES2991091T3 (es) | 2017-06-05 | 2024-12-02 | Univ Mie | Proteína de unión a antígeno que reconoce el péptido derivado de MAGE-A4 |
| JP7722629B2 (ja) | 2017-07-04 | 2025-08-13 | キュアバック エスイー | 新規核酸分子 |
| MX2020001879A (es) | 2017-08-18 | 2020-07-29 | Gritstone Oncology Inc | Proteínas de fijación al antígeno que se dirigen a antígenos compartidos. |
| CN111315769A (zh) | 2017-09-06 | 2020-06-19 | 加州理工学院 | 信号传导和抗原呈递双功能受体(sabr) |
| AU2018395397A1 (en) | 2017-12-28 | 2020-08-06 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared antigens |
| KR102892744B1 (ko) | 2018-04-19 | 2025-11-28 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Mage-b2 특이성을 갖는 t 세포 수용체 및 이의 용도 |
| TW202000907A (zh) | 2018-05-23 | 2020-01-01 | 美商葛利史東腫瘤科技公司 | 共有抗原 |
| US20200291127A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| US20200291116A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| US20200291128A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
-
2015
- 2015-01-21 GB GBGB1501017.6A patent/GB201501017D0/en not_active Ceased
- 2015-12-16 PE PE2017000542A patent/PE20170940A1/es unknown
- 2015-12-16 EA EA202190587A patent/EA202190587A3/ru unknown
- 2015-12-16 EP EP19199114.0A patent/EP3620168A1/en not_active Withdrawn
- 2015-12-16 PH PH1/2017/500484A patent/PH12017500484B1/en unknown
- 2015-12-16 CR CR20170282A patent/CR20170282A/es unknown
- 2015-12-16 DK DK19199125.6T patent/DK3626731T3/da active
- 2015-12-16 CN CN202011432405.4A patent/CN112646021A/zh active Pending
- 2015-12-16 DK DK19199098.5T patent/DK3616706T3/da active
- 2015-12-16 DK DK19170191.1T patent/DK3545965T3/da active
- 2015-12-16 RS RS20211276A patent/RS62448B1/sr unknown
- 2015-12-16 MX MX2017008329A patent/MX377144B/es active IP Right Grant
- 2015-12-16 RS RS20211341A patent/RS62508B1/sr unknown
- 2015-12-16 SI SI201531721T patent/SI3626729T1/sl unknown
- 2015-12-16 SI SI201531025T patent/SI3236985T2/sl unknown
- 2015-12-16 EA EA201791150A patent/EA201791150A1/ru unknown
- 2015-12-16 CN CN202011429073.4A patent/CN112646025A/zh active Pending
- 2015-12-16 DK DK19199101.7T patent/DK3626729T3/da active
- 2015-12-16 EP EP19170191.1A patent/EP3545965B1/en active Active
- 2015-12-16 EP EP15813809.9A patent/EP3236985B2/en active Active
- 2015-12-16 EP EP19199125.6A patent/EP3626731B1/en active Active
- 2015-12-16 WO PCT/EP2015/080018 patent/WO2016102272A1/en not_active Ceased
- 2015-12-16 CN CN202011429041.4A patent/CN112538109A/zh active Pending
- 2015-12-16 EP EP20172206.3A patent/EP3715357B1/en active Active
- 2015-12-16 SG SG11201703322UA patent/SG11201703322UA/en unknown
- 2015-12-16 CA CA2972126A patent/CA2972126A1/en active Pending
- 2015-12-16 MA MA41237A patent/MA41237B1/fr unknown
- 2015-12-16 EP EP19199098.5A patent/EP3616706B1/en active Active
- 2015-12-16 MA MA40136A patent/MA40136A1/fr unknown
- 2015-12-16 SI SI201531682T patent/SI3545965T1/sl unknown
- 2015-12-16 RS RS20211033A patent/RS62237B1/sr unknown
- 2015-12-16 AU AU2015371490A patent/AU2015371490B2/en not_active Ceased
- 2015-12-16 EP EP19199101.7A patent/EP3626729B1/en active Active
- 2015-12-16 BR BR112017008972-6A patent/BR112017008972A2/pt not_active Application Discontinuation
- 2015-12-16 EP EP19199106.6A patent/EP3626730A1/en not_active Withdrawn
- 2015-12-16 CN CN201580055141.6A patent/CN107001414A/zh active Pending
- 2015-12-16 KR KR1020177017192A patent/KR102284493B1/ko not_active Expired - Fee Related
- 2015-12-16 PL PL15813809.9T patent/PL3236985T5/pl unknown
- 2015-12-16 JP JP2017518096A patent/JP6906156B2/ja not_active Expired - Fee Related
- 2015-12-16 RS RS20191606A patent/RS59836B2/sr unknown
- 2015-12-16 MA MA49158A patent/MA49158B1/fr unknown
- 2015-12-21 US US14/975,952 patent/US10064926B2/en active Active
- 2015-12-21 TW TW104142988A patent/TWI687436B/zh not_active IP Right Cessation
- 2015-12-21 AR ARP150104228A patent/AR103220A1/es not_active Application Discontinuation
-
2016
- 2016-11-21 US US15/357,757 patent/US20170080070A1/en not_active Abandoned
-
2017
- 2017-03-07 IL IL250989A patent/IL250989B/en active IP Right Grant
- 2017-05-31 CL CL2017001391A patent/CL2017001391A1/es unknown
-
2018
- 2018-03-09 US US15/917,098 patent/US20180207252A1/en not_active Abandoned
- 2018-03-12 US US15/918,788 patent/US11406693B2/en active Active
- 2018-09-18 US US16/134,422 patent/US20190000947A1/en not_active Abandoned
-
2020
- 2020-06-29 US US16/915,308 patent/US20200376103A1/en not_active Abandoned
- 2020-08-04 AU AU2020213295A patent/AU2020213295B2/en not_active Ceased
- 2020-08-04 AU AU2020213294A patent/AU2020213294B2/en not_active Ceased
- 2020-09-11 US US17/018,915 patent/US20200405831A1/en not_active Abandoned
-
2021
- 2021-03-26 JP JP2021052978A patent/JP7713309B2/ja active Active
- 2021-04-30 US US17/245,918 patent/US11786583B2/en active Active
- 2021-07-14 AR ARP210101973A patent/AR122964A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510628A5 (enExample) | ||
| JP2019510465A5 (enExample) | ||
| JP2018529320A5 (enExample) | ||
| JP2019506838A5 (enExample) | ||
| JP2019502360A5 (enExample) | ||
| JP2018536383A5 (enExample) | ||
| JP2021168652A5 (enExample) | ||
| JP2018519243A5 (enExample) | ||
| JP2021514178A5 (enExample) | ||
| JP2018511321A5 (enExample) | ||
| JP2018520653A5 (enExample) | ||
| JP2017525336A5 (enExample) | ||
| JP2018518937A5 (enExample) | ||
| JP2019511214A5 (enExample) | ||
| RU2017137142A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2017502076A5 (enExample) | ||
| JP2018521641A5 (enExample) | ||
| JP2018518956A5 (enExample) | ||
| JP2024099580A5 (enExample) | ||
| JP2020530759A5 (enExample) | ||
| JP2017524337A5 (enExample) | ||
| JP2021535900A5 (enExample) | ||
| JP2018530579A (ja) | ウイルス性癌ネオエピトープのための組成物および方法 | |
| CA3132041A1 (en) | Identification of neoantigens with mhc class ii model | |
| JP2013521789A5 (enExample) |